Human Immunodeficiency Virus type 1 (HIV-1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 Human Immunodeficiency Virus type 1 (HIV-1) is a retrovirus that infects humans and is the primary cause of acquired immunodeficiency syndrome (AIDS). It belongs to the Lentivirus genus of the Retroviridae family. HIV-1 is one of the two major types of HIV, the other being HIV-2. HIV-1 is transmitted by exchanging body fluids, including blood, semen, vaginal fluids, rectal fluids, and breast milk. The most common transmission routes include unprotected sexual contact with an infected person, sharing needles or syringes with an infected person, and transmission from an infected mother to her child during childbirth or breastfeeding. Once the virus enters the body, it primarily targets and infects CD4+ T cells, a type of white blood cell crucial for the immune system's proper functioning. As the virus replicates, it progressively destroys these CD4+ T cells, weakening the immune system and making the person more susceptible to opportunistic infections and certain cancers. The course of HIV infection is divided into several stages:

·       Acute HIV infection: This occurs within a few weeks after the initial infection and may cause flu-like symptoms such as headache, fever, sore throat, swollen lymph nodes, and rash.

·       Clinical latency: After the initial stage, HIV remains in the body but may not cause noticeable symptoms for an extended period. However, the virus continues to replicate and damage the immune system during this time.

·       Acquired Immunodeficiency Syndrome (AIDS): If HIV is left untreated, the immune system becomes severely damaged, and the person is diagnosed with AIDS. At this stage, the individual becomes highly susceptible to opportunistic infections and certain cancers.

·       HIV can be managed effectively with antiretroviral therapy (ART), a combination of medications that helps suppress viral replication and maintain a healthy immune system. While ART does not cure HIV, it allows people living with the virus to lead relatively healthy lives and significantly reduces the risk of transmitting it to others.

Thelansis’s “Human Immunodeficiency Virus type 1 (HIV-1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Human Immunodeficiency Virus type 1 (HIV-1) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Human Immunodeficiency Virus type 1 (HIV-1) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Human Immunodeficiency Virus type 1 (HIV-1) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Human Immunodeficiency Virus type 1 (HIV-1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more